Literature DB >> 23677322

Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing a manno-heptose capsule.

Andrew E Scott1, Thomas R Laws, Riccardo V D'Elia, Margaret G M Stokes, Tannistha Nandi, E Diane Williamson, Patrick Tan, Joann L Prior, Timothy P Atkins.   

Abstract

Melioidosis is a severe infectious disease caused by Burkholderia pseudomallei. It is highly resistant to antibiotic treatment, and there is currently no licensed vaccine. Burkholderia thailandensis is a close relative of Burkholderia pseudomallei but is essentially avirulent in mammals. In this report, we detail the protective efficacy of immunization with live B. thailandensis E555, a strain which has been shown to express an antigenic capsule similar to that of B. pseudomallei. Immunization with E555 induced significant protection against a lethal intraperitoneal B. pseudomallei challenge in a mouse model of infection, with no mice succumbing to infection over the course of the study, even with challenges of up to 6,000 median lethal doses. By comparison, mice immunized with B. thailandensis not expressing a B. pseudomallei-like capsule had significantly decreased levels of protection. E555-immunized mice had significantly higher levels of IgG than mice immunized with noncapsulated B. thailandensis, and these antibody responses were primarily directed against the capsule.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23677322      PMCID: PMC3697456          DOI: 10.1128/CVI.00113-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  42 in total

1.  Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins.

Authors:  S M Jones; J F Ellis; P Russell; K F Griffin; P C F Oyston
Journal:  J Med Microbiol       Date:  2002-12       Impact factor: 2.472

2.  Characterization of Burkholderia pseudomallei and Burkholderia pseudomallei-like strains.

Authors:  P J Brett; D Deshazer; D E Woods
Journal:  Epidemiol Infect       Date:  1997-04       Impact factor: 2.451

3.  Antilipopolysaccharide II: an antibody protective against fatal melioidosis.

Authors:  C Charuchaimontri; Y Suputtamongkol; C Nilakul; W Chaowagul; P Chetchotisakd; N Lertpatanasuwun; S Intaranongpai; P J Brett; D E Woods
Journal:  Clin Infect Dis       Date:  1999-10       Impact factor: 9.079

Review 4.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

5.  The Burkholderia pseudomallei Δasd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice.

Authors:  Michael H Norris; Katie L Propst; Yun Kang; Steven W Dow; Herbert P Schweizer; Tung T Hoang
Journal:  Infect Immun       Date:  2011-08-01       Impact factor: 3.441

6.  Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis.

Authors:  Michelle Nelson; Joann L Prior; M Stephen Lever; Helen E Jones; Timothy P Atkins; Richard W Titball
Journal:  J Med Microbiol       Date:  2004-12       Impact factor: 2.472

7.  Virulence of clinical and environmental isolates of Burkholderia oklahomensis and Burkholderia thailandensis in hamsters and mice.

Authors:  David Deshazer
Journal:  FEMS Microbiol Lett       Date:  2007-12       Impact factor: 2.742

8.  Relapse in melioidosis: incidence and risk factors.

Authors:  W Chaowagul; Y Suputtamongkol; D A Dance; A Rajchanuvong; J Pattara-arechachai; N J White
Journal:  J Infect Dis       Date:  1993-11       Impact factor: 5.226

9.  Melioidosis: pathogenesis and immunity in mice and hamsters. III. Effect of vaccination with avirulent strains of Pseudomonas pseudomallei on the resistance to the establishment and the resistance to the progress of respiratory melioidosis caused by virulent strains; all-or-none aspects of this disease.

Authors:  A M DANNENBERG; E M SCOTT
Journal:  J Immunol       Date:  1960-03       Impact factor: 5.422

10.  A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins.

Authors:  Ashraful Haque; Karen Chu; Anna Easton; Mark P Stevens; Edouard E Galyov; Tim Atkins; Rick Titball; Gregory J Bancroft
Journal:  J Infect Dis       Date:  2006-09-25       Impact factor: 5.226

View more
  24 in total

Review 1.  Novel multi-component vaccine approaches for Burkholderia pseudomallei.

Authors:  L Morici; A G Torres; R W Titball
Journal:  Clin Exp Immunol       Date:  2019-04-08       Impact factor: 4.330

2.  Recent Advances in Burkholderia mallei and B. pseudomallei Research.

Authors:  Christopher L Hatcher; Laura A Muruato; Alfredo G Torres
Journal:  Curr Trop Med Rep       Date:  2015-06

Review 3.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

4.  Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Shawn M Zimmerman; Jeremy S Dyke; Tomislav P Jelesijevic; Frank Michel; Eric R Lafontaine; Robert J Hogan
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

5.  Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis.

Authors:  Andrew E Scott; Mary N Burtnick; Margaret G M Stokes; Adam O Whelan; E Diane Williamson; Timothy P Atkins; Joann L Prior; Paul J Brett
Journal:  Infect Immun       Date:  2014-05-27       Impact factor: 3.441

6.  Characterization of Burkholderia pseudomallei Strains Using a Murine Intraperitoneal Infection Model and In Vitro Macrophage Assays.

Authors:  Susan L Welkos; Christopher P Klimko; Steven J Kern; Jeremy J Bearss; Joel A Bozue; Robert C Bernhards; Sylvia R Trevino; David M Waag; Kei Amemiya; Patricia L Worsham; Christopher K Cote
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

7.  Characterization of the Burkholderia mallei tonB Mutant and Its Potential as a Backbone Strain for Vaccine Development.

Authors:  Tiffany M Mott; Sudhamathi Vijayakumar; Elena Sbrana; Janice J Endsley; Alfredo G Torres
Journal:  PLoS Negl Trop Dis       Date:  2015-06-26

8.  Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machinery.

Authors:  Fatima Garcia-Quintanilla; Jeremy A Iwashkiw; Nancy L Price; Chad Stratilo; Mario F Feldman
Journal:  Front Microbiol       Date:  2014-07-29       Impact factor: 5.640

9.  New insights from the 7th World Melioidosis Congress 2013.

Authors:  Herbert P Schweizer; Direk Limmathurotsakul; Sharon J Peacock
Journal:  Emerg Infect Dis       Date:  2014-07       Impact factor: 6.883

10.  Vaccines for the Prevention of Melioidosis and Glanders.

Authors:  Monica M Johnson; Kristy M Ainslie
Journal:  Curr Trop Med Rep       Date:  2017-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.